News Feed Opinion Blog Career Insight Dialogues Celebrities Oncolibrary
Positive Societies Drugs Stories History Cancer Center Near Me Cancer Types Immune Oncology Oncologist Near Me
November, 2024
November 2024
M T W T F S S
 123
45678910
11121314151617
18192021222324
252627282930  
Myeloma Paper of the Day, June 11th, suggested by Robert Orlowski
Jun 11, 2024, 12:59

Myeloma Paper of the Day, June 11th, suggested by Robert Orlowski

Robert Orlowski shared on X:

“Myeloma Paper of the Day: Phase II trial of ixazomib/daratumumab/dexamethasone in relapsed/refractory myeloma finds ORR of 64.4%, VGPR rate of 30.5%, median PFS 16.8 months, and low rate of neuropathy (18.0% all grades, 1.6% grade ≥3).”

Source: Robert Orlowski/X

Ixazomib plus daratumumab and dexamethasone: Final analysis of a phase 2 study among patients with relapsed/refractory multiple myeloma

Authors: Sosana Delimpasi, Meletios Dimopoulos, Jan Straub, Argiris Symeonidis, Luděk Pour, Roman Hájek, Cyrille Touzeau, Viralkumar Bhanderi, Jesus Berdeja, Petr Pavlíček, Jeffrey Matous, Pawel Robak, Kaveri Suryanarayan, Alison Miller, Miguel Villarreal, Dasha Cherepanov, Jaydeep Srimani, Huilan Yao, Richard Labotka, and Robert Orlowski.

Myeloma Paper of the Day, June 11th, suggested by Robert Orlowski

Other posts featuring Robert Orlowski on OncoDaily.

Robert Orlowski holds multiple positions at The University of Texas MD Anderson Cancer Center, including Chairman, Ad Interim Director of Myeloma, and Professor of Medicine in the Departments of Lymphoma/Myeloma and Experimental Therapeutics within the Division of Cancer Medicine.

Additionally, he chairs the SWOG Barlogie/Salmon Myeloma Committee, which is part of the National Clinical Trials Network, dedicated to advancing new therapies and understanding the biology of myeloma.

Alison Miller Argiris Symeonidis cancer Cyrille Touzeau Daratumumab Dasha Cherepanov dexamethasone Huilan Yao ixazomib Jan Straub Jaydeep Srimani Jeffrey Matous Jesus Berdeja Kaveri Suryanarayan Luděk Pour MD Anderson Cancer Center Meletios Dimopoulos Miguel Villarreal multiple myeloma Myeloma Paper of the Day OncoDaily Oncology Pawel Robak Petr Pavlíček R/R myeloma Richard Labotka Robert Orlowski Roman Hájek Sosana Delimpasi Viralkumar Bhanderi
Special Coverage
Career
Nov 15, 2024, 07:34
Last chance to apply for Manchester Cancer Research Centre's PhD opportunities for 2025
Insight
Nov 15, 2024, 07:12
Dominique Stuijt: Patient-reported barriers and facilitators to using mHealth during cancer treatment
Blog
Nov 15, 2024, 07:08
Harry Greenspun: Great opening day of the Milken Institute Future's of Health Summit
Insight
Nov 15, 2024, 07:05
Susanna Greer: A New Playbook for Head and Neck Cancer Treatment
Blog
Nov 15, 2024, 07:03
Factors enabling oncologists to cope with work-related stress - ESMO
Celebrities
Nov 15, 2024, 06:53
Robert De Niro and Prostate Cancer: How He Went Against, How He Survived, and More
Blog
Nov 15, 2024, 06:33
Sendurai Mani: The Power of Determination
Blog
Nov 15, 2024, 05:57
A message from Tedros Adhanom Ghebreyesus during London Global Cancer Week
Blog
Nov 15, 2024, 05:39
Connect with health leaders committed to cancer prevention at the PROTECT EUROPE showcase event - European Cancer Organisation
Insight
Nov 15, 2024, 02:40
Patrick Hwu was Named one of the 2024 Florida 500 for Leadership in Medicine and Cancer Research
Blog
Nov 14, 2024, 17:57
European Cancer Organisation's Memorandum of Understanding with UNFPA
Blog
Nov 14, 2024, 17:51
Research is for everyone. Every voice and experience matters - Young Lung Cancer Initiative